Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: shares of Alto Neuroscience carry a consensus rating of “Moderate Buy” from eight analysts (six buys, one hold, one sell), with an average 12‑month price target of $26.50.
• Institutional flows: several hedge funds have recently added or increased positions—AlphaCore doubled its stake, Bridgeway and Ieq raised holdings, and new stakes were reported from Y Intercept Hong Kong and ExodusPoint—signaling growing institutional interest.
• Company and stock snapshot: Alto is a clinical‑stage biotech using EEG and multimodal biomarkers for precision treatment in neuropsychiatric disorders, and the stock trades around $20.52 with a market cap of about $638M and a 12‑month range of $1.60–$21.57.

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $26.50.

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Alto Neuroscience in a report on Monday, December 29th. Chardan Capital increased their target price on shares of Alto Neuroscience from $15.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, January 5th. Robert W. Baird lifted their price target on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Thursday, November 13th. Jefferies Financial Group increased their price objective on Alto Neuroscience from $15.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, November 12th. Finally, Wall Street Zen upgraded Alto Neuroscience from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. AlphaCore Capital LLC increased its holdings in shares of Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company's stock valued at $44,000 after purchasing an additional 10,000 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Alto Neuroscience during the 2nd quarter worth approximately $85,000. Bridgeway Capital Management LLC increased its position in shares of Alto Neuroscience by 43.5% during the third quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company's stock worth $312,000 after purchasing an additional 23,553 shares in the last quarter. Ieq Capital LLC raised its position in shares of Alto Neuroscience by 19.6% in the fourth quarter. Ieq Capital LLC now owns 75,294 shares of the company's stock valued at $1,340,000 after buying an additional 12,315 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new stake in Alto Neuroscience in the 4th quarter valued at about $334,000.

Alto Neuroscience Stock Performance

Shares of Alto Neuroscience stock opened at $20.52 on Friday. The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. The stock's fifty day moving average price is $17.32 and its 200-day moving average price is $12.19. The firm has a market cap of $637.56 million, a P/E ratio of -8.96 and a beta of 2.52. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $21.57.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.